FDA Warning Letter Renews Concerns About Barring Inspection Photos
This article was originally published in The Rose Sheet
Executive Summary
An FDA warning letter issued in August to OTC drug manufacturer Homeolab has revived discussion about companies' options when it comes to investigator photographs during facility inspections, prompting fresh insight from industry attorneys on the issue's legal underpinning and existing case law.